White paper

Scaling up mAb process development from 250mL to 5L bioreactor with consistent yield in Culture Biosciences cloud-connected bioreactors

In the highly competitive antibody development market, speed to clinic is critical. Accelerating the development of a robust process that delivers high-yield and high-quality product gives biotech and pharma companies an edge. Design of Experiments (DOE)-based screening early or during scale-down studies enables definition of design space and critical process parameters (CPPs) in accordance with critical quality attributes (CQAs). Together, DOE-based exploration of the design space and seamless scale up ensure robustness and speed of process development.

Download this white paper to learn about:

  • Successful scale-up of CHO cultures from 250mL to 5L
  • Comparability of IgG and VCD between 250mL, 5L and shake flask cultures
  • Comparability of glucose and lactate concentrations between 250mL and 5L cultures

Complete the form to download the full PDF

Keep exploring

White paper

Continuous monitoring with Culture Biosciences 250mL Bioreactors and 908 Devices MAVERICK

April 3, 2024
White paper

AAV Production in Culture Biosciences’ 250mL Bioreactors

January 17, 2024